Study of the Expression of Heat Shock Proteins in Populations of B Lymphocytes in Human Tonsils

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-26

Study Completion Date

2014-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has recently been shown that various HSPs are strongly expressed in B lymphomas. Indeed, HSP90 stabilizes the protein Bcl-6 in diffuse large-cell B lymphomas. Pharmacological inhibition of HSP90 in vitro induced apoptosis in lymphoma cells (Cerchietti et al. Nat. Medicine, 2009, 1369-1376). In addition, HSP110 is strongly expressed in non-Hodgkin lymphomas, and targeting this HSP at the cell surface using specific antibodies could constitute a future therapy (Zappasodi et al. Blood, 2011, 4421-4430). Despite the importance of these proteins in the development of lymphomas, their expression and their role in the activation of normal B lymphocytes and the normal development of germinal centres is not known.

The expression of Heat shock proteins should vary among the different B lymphocyte populations present in the tonsils (naïve B cells, memory B cells, germinal centre B cells).

The aim of this study is to establish an expression profile for heat shock proteins in populations of B lymphocytes in human tonsils

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region

NCT04859920

Diffuse Large Cell Diffuse Lymphoma Follicular Lymphoma

COMPLETED

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

NCT03985696

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)

UNKNOWN NA

Low Grade Lymphoma

NCT01698866

Indolent Lymphoproliferative Disorders

UNKNOWN PHASE4

Treatment of Diffuse Large B Cell Lymphoma

NCT01949818

Diffuse Large B Cell Lymphoma

UNKNOWN PHASE4

Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma

NCT04183569

Lymphoma, Large B-Cell, Diffuse

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tonsillectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient

Group Type EXPERIMENTAL

tonsillectomy

Intervention Type PROCEDURE

blood sample

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tonsillectomy

Intervention Type PROCEDURE

blood sample

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons who have provided oral consent
* Tonsillectomy in children or adults

Exclusion Criteria

* Persons without national health insurance cover
* Adults under guardianship
* Pregnant or breast-feeding women
* Persons with positive HIV or HCV serology

Eligible Sex

ALL

Accepts Healthy Volunteers

No